Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (887
)
Hodgkin Lymphoma (59
)
Non-Hodgkin’s Lymphoma (887
)
Hodgkin Lymphoma (59
)
›
Associations
(1022)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
pirtobrutinib
Sensitive: A1 - Approval
Eli Lilly Press Release - 4 days (New A1)
pirtobrutinib
Sensitive
:
A1
Eli Lilly Press Release - 4d
pirtobrutinib
Sensitive: A1 - Approval
Eli Lilly Press Release - 4 days
pirtobrutinib
Sensitive
:
A1
Eli Lilly Press Release - 4 days - (New A1)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
mosunetuzumab
Sensitive: A1 - Approval
NCCN - 6 days (New A2)
mosunetuzumab
Sensitive
:
A1
NCCN - 6d
mosunetuzumab
Sensitive: A1 - Approval
NCCN - 6 days
mosunetuzumab
Sensitive
:
A1
NCCN - 6 days - (New A2)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
acalabrutinib
Sensitive: A2 - Guideline
NCCN - 6 days (New A2)
acalabrutinib
Sensitive
:
A2
NCCN - 6d
acalabrutinib
Sensitive: A2 - Guideline
NCCN - 6 days
acalabrutinib
Sensitive
:
A2
NCCN - 6 days - (New A2)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
tazemetostat
Sensitive: A2 - Guideline
NCCN - 6 days (New A2)
tazemetostat
Sensitive
:
A2
NCCN - 6d
tazemetostat
Sensitive: A2 - Guideline
NCCN - 6 days
tazemetostat
Sensitive
:
A2
NCCN - 6 days - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
Bv-AVE-PC
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
Bv-AVE-PC
Sensitive
:
A2
NCCN - 2wk
Bv-AVE-PC
Sensitive: A2 - Guideline
NCCN - 2 weeks
Bv-AVE-PC
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
AEPA-CAPDAC
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
AEPA-CAPDAC
Sensitive
:
A2
NCCN - 2wk
AEPA-CAPDAC
Sensitive: A2 - Guideline
NCCN - 2 weeks
AEPA-CAPDAC
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
CVbP
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
CVbP
Sensitive
:
A2
NCCN - 2wk
CVbP
Sensitive: A2 - Guideline
NCCN - 2 weeks
CVbP
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
CHOP
Sensitive
:
A2
NCCN - 2wk
CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks
CHOP
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
OEPA
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
OEPA
Sensitive
:
A2
NCCN - 2wk
OEPA
Sensitive: A2 - Guideline
NCCN - 2 weeks
OEPA
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
ABVE-PC
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
ABVE-PC
Sensitive
:
A2
NCCN - 2wk
ABVE-PC
Sensitive: A2 - Guideline
NCCN - 2 weeks
ABVE-PC
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
cisplatin
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
cisplatin
Sensitive
:
A2
NCCN - 3wk
cisplatin
Sensitive: A2 - Guideline
NCCN - 3 weeks
cisplatin
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
AspaMetDex
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
AspaMetDex
Sensitive
:
A2
NCCN - 3wk
AspaMetDex
Sensitive: A2 - Guideline
NCCN - 3 weeks
AspaMetDex
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
DDGP
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
DDGP
Sensitive
:
A2
NCCN - 3wk
DDGP
Sensitive: A2 - Guideline
NCCN - 3 weeks
DDGP
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
SMILE
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
SMILE
Sensitive
:
A2
NCCN - 3wk
SMILE
Sensitive: A2 - Guideline
NCCN - 3 weeks
SMILE
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
RG6026
Sensitive: B - Late Trials
Roche Press Release - 3 weeks (New B)
RG6026
Sensitive
:
B
Roche Press Release - 3wk
RG6026
Sensitive: B - Late Trials
Roche Press Release - 3 weeks
RG6026
Sensitive
:
B
Roche Press Release - 3 weeks - (New B)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
ALK positive
Non-Hodgkin’s Lymphoma
ALK positive
Non-Hodgkin’s Lymphoma
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Lymphoma
No biomarker
Lymphoma
axicabtagene ciloleucel
Resistant: A1 - Approval
axicabtagene ciloleucel
Resistant
:
A1
axicabtagene ciloleucel
Resistant: A1 - Approval
axicabtagene ciloleucel
Resistant
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
No biomarker
Burkitt Lymphoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
No biomarker
Burkitt Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
TNFRSF8 positive
Hodgkin Lymphoma
TNFRSF8 positive
Hodgkin Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
CD20 expression
Non-Hodgkin’s Lymphoma
CD20 expression
Non-Hodgkin’s Lymphoma
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login